麗寶新藥麗寶新藥麗寶新藥麗寶新藥麗寶新藥
  • About us
    • Company Introduction
    • Management Team
    • Strategic Alliance
  • Research & Development
    • Core Product
      • LIB-101
    • R&D Progress
    • Clinical Trials
  • Our Advantages
    • Technological Advantages
    • Development Roadmap
  • Press Release
  • Investor Relations
    • Financial Information
    • Shareholder Section
    • Material Information
      • Important Announcements
      • Market Observation Post System
  • CSR
  • Careers
  • Contact Us
  • English
    • 中文(台灣)
    • 日本語

Announcements (QA)

11/22

生華科CX-5461合併免疫抑制劑治療MSS CRC 第1-2期人體臨床試驗已獲美FDA核准執行

11/20

生華科CX-5461合併免疫抑制劑治療MSS CRC 第1-2期人體臨床試驗已獲美FDA核准執行

10/2

生華科CX-5461合併免疫抑制劑治療MSS CRC 第1-2期人體臨床試驗已獲美FDA核准執行

9/13

生華科CX-5461合併免疫抑制劑治療MSS CRC 第1-2期人體臨床試驗已獲美FDA核准執行

ABOUT US
CONTACT US
PRESS RELEASE
© Copyright | LIBO PHARMA CORP. | All rights reserved | Private Policy 2024
linkedin